Clinical TrialJul 2, 2026, 01:01 AM
Molecular Partners doses first patients in US MP0712 study
AI Summary
Molecular Partners and Orano Med announced that the first patients have been dosed in the US multicenter Phase 1/2a study of MP0712, their lead Radio-DARPin candidate. MP0712 targets DLL3, a protein highly expressed in small cell lung cancer and other neuroendocrine tumors. The study is actively recruiting at five sites, with initial data expected in the coming months of 2026 and comprehensive efficacy data anticipated in 2027.
Key Highlights
- First patients dosed in US Phase 1/2a study of Radio-DARPin MP0712.
- MP0712 targets DLL3, highly expressed in over 85% of SCLC tumors.
- Five US sites are actively recruiting patients for the study.
- Initial data from the Phase 1/2a study expected in coming months (2026).
- Comprehensive efficacy data for MP0712 anticipated in 2027.
- Patients receive up to four doses of 212Pb-labeled MP0712.
- The program utilizes a "matched-pair" approach with 203Pb-labeled MP0712 for imaging.
Price Impact
More from MOLN
Clinical TrialJun 1, 7:26 AM
Molecular Partners Dosing Patients in Phase 1 MP0712 Trial; Presents at ASCO/SNMMI
Clinical TrialMay 30, 8:02 AM
Molecular Partners to Present MP0712 Phase 1/2a Data at ASCO, SNMMI
Business UpdateMay 26, 4:02 PM
Molecular Partners to Participate in TD Cowen Oncology Innovation Summit